WallStreetZenWallStreetZen

NASDAQ: GPCR
Structure Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for GPCR

Based on 5 analysts offering 12 month price targets for Structure Therapeutics Inc

Min Forecast
$50.00+141.08%
Avg Forecast
$67.80+226.9%
Max Forecast
$89.00+329.12%

Should I buy or sell GPCR stock?

Based on 5 analysts offering ratings for Structure Therapeutics Inc.

Strong Buy
Strong Buy
3 analysts 60%
Buy
2 analysts 40%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although GPCR's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates GPCR as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -8.02% per year. Learn More

Be the first to know when Wall Street analysts revise their GPCR stock forecasts and price targets.

GPCR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-06-23
lockedlocked$00.00+00.00%2025-06-23
lockedlocked$00.00+00.00%2025-05-12
lockedlocked$00.00+00.00%2025-05-02
lockedlocked$00.00+00.00%2025-01-08

1 of 1

Forecast return on equity

Is GPCR forecast to generate an efficient return?

Company
-24.95%
Industry
165.61%
Market
89.98%
GPCR's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is GPCR forecast to generate an efficient return on assets?

Company
-23.74%
Industry
43.22%
GPCR is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

GPCR earnings per share forecast

What is GPCR's earnings per share in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
-$0.83
Avg 2 year Forecast
-$1.58
Avg 3 year Forecast
-$1.71

GPCR revenue forecast

What is GPCR's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$500.0M
Avg 2 year Forecast
$883.5M
Avg 3 year Forecast
$611.0M

GPCR vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GPCR$20.74$67.80+226.90%Strong Buy
CVAC$5.43$6.83+25.84%Hold
AUPH$8.47N/AN/A
VRDN$13.98$36.00+157.51%Buy
MNKD$3.74N/AN/A
View Top Biotech Stocks

Structure Therapeutics Stock Forecast FAQ

Is Structure Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: GPCR) stock is to Strong Buy GPCR stock.

Out of 5 analysts, 3 (60%) are recommending GPCR as a Strong Buy, 2 (40%) are recommending GPCR as a Buy, 0 (0%) are recommending GPCR as a Hold, 0 (0%) are recommending GPCR as a Sell, and 0 (0%) are recommending GPCR as a Strong Sell.

If you're new to stock investing, here's how to buy Structure Therapeutics stock.

What is GPCR's earnings growth forecast for 2025-2027?

(NASDAQ: GPCR) Structure Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.97%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.83%.

Structure Therapeutics's earnings in 2025 is -$143,323,000.On average, 8 Wall Street analysts forecast GPCR's earnings for 2025 to be -$143,922,426, with the lowest GPCR earnings forecast at -$270,998,091, and the highest GPCR earnings forecast at $307,246,243. On average, 8 Wall Street analysts forecast GPCR's earnings for 2026 to be -$272,517,061, with the lowest GPCR earnings forecast at -$343,494,396, and the highest GPCR earnings forecast at -$201,953,991.

In 2027, GPCR is forecast to generate -$294,662,956 in earnings, with the lowest earnings forecast at -$414,264,598 and the highest earnings forecast at -$203,680,094.

What is GPCR's revenue growth forecast for 2025-2029?

(NASDAQ: GPCR) Structure Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.23%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.33%.

Structure Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast GPCR's revenue for 2025 to be $86,305,124,500, with the lowest GPCR revenue forecast at $86,305,124,500, and the highest GPCR revenue forecast at $86,305,124,500. On average, 1 Wall Street analysts forecast GPCR's revenue for 2028 to be $152,492,524,479, with the lowest GPCR revenue forecast at $152,492,524,479, and the highest GPCR revenue forecast at $152,492,524,479.

In 2029, GPCR is forecast to generate $105,457,439,898 in revenue, with the lowest revenue forecast at $2,537,370,660 and the highest revenue forecast at $286,205,053,867.

What is GPCR's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: GPCR) forecast ROA is -23.74%, which is lower than the forecast US Biotechnology industry average of 43.22%.

What is GPCR's Price Target?

According to 5 Wall Street analysts that have issued a 1 year GPCR price target, the average GPCR price target is $67.80, with the highest GPCR stock price forecast at $89.00 and the lowest GPCR stock price forecast at $50.00.

On average, Wall Street analysts predict that Structure Therapeutics's share price could reach $67.80 by Jun 23, 2026. The average Structure Therapeutics stock price prediction forecasts a potential upside of 226.9% from the current GPCR share price of $20.74.

What is GPCR's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: GPCR) Structure Therapeutics's current Earnings Per Share (EPS) is -$2.61. On average, analysts forecast that GPCR's EPS will be -$0.83 for 2025, with the lowest EPS forecast at -$1.57, and the highest EPS forecast at $1.78. On average, analysts forecast that GPCR's EPS will be -$1.58 for 2026, with the lowest EPS forecast at -$1.99, and the highest EPS forecast at -$1.17. In 2027, GPCR's EPS is forecast to hit -$1.71 (min: -$2.40, max: -$1.18).

What is GPCR's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: GPCR) forecast ROE is -24.95%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.